Discovery of novel α‐carboline derivatives as glycogen synthase kinase‐3β inhibitors for the treatment of Alzheimer's disease
作者:Huanhua Chen、Chong Yu、Wenjie Liu、Chengze Zhu、Xiaowen Jiang、Chang Xu、Wenwu Liu、Yaoguang Huang、Zihua Xu、Qingchun Zhao
DOI:10.1002/ardp.202200156
日期:2022.10
and behavioral disturbances, ultimately resulting in death. The critical roles of glycogen synthase kinase-3β (GSK-3β) in tau pathology have also received considerable attention. Based on molecular docking studies, a series of novel α-carboline derivatives were designed, synthesized, and evaluated as GSK-3β inhibitors for their various biological activities. Among them, compound ZCH-9 showed the most
阿尔茨海默病 (Alzheimer's disease, AD) 是一种慢性进行性神经退行性疾病,以不可逆的认知障碍、记忆力减退和行为障碍为特征,最终导致死亡。糖原合酶激酶 3β (GSK-3β) 在 tau 病理学中的关键作用也受到了相当多的关注。基于分子对接研究,设计、合成了一系列新型α-咔啉衍生物作为GSK-3β抑制剂的各种生物活性。其中,化合物ZCH-9对GSK-3β的抑制活性最强,IC 50值为1.71 ± 0.09 µM。细胞毒性试验表明ZCH-9对细胞系 SH-SY5Y、HepG2 和 HL-7702 具有低细胞毒性。此外,蛋白质印迹分析表明,ZCH-9有效抑制冈田酸处理的 SH-SY5Y 细胞中 tau 蛋白的过度磷酸化。在整个分子动力学模拟过程中分析并进一步阐明了ZCH-9和 GSK-3β之间的结合模式。总的来说,这些结果表明,基于 α-咔啉的小分子化合物可以作为靶向 GSK-3β